Stephen M Ansell

Stephen M Ansell

UNVERIFIED PROFILE

Are you Stephen M Ansell?   Register this Author

Register author
Stephen M Ansell

Stephen M Ansell

Publications by authors named "Stephen M Ansell"

Are you Stephen M Ansell?   Register this Author

100Publications

2358Reads

42Profile Views

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Cancer Immunol Res 2019 Aug 5. Epub 2019 Aug 5.

Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, Iowa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0821DOI Listing
August 2019

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Genet Epidemiol 2019 Aug 13. Epub 2019 Aug 13.

Center for Neuroengineering and Therapeutics, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gepi.22242DOI Listing
August 2019

Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.

Authors:
Stephen M Ansell

Cancer J 2018 Sep/Oct;24(5):249-253

From the Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000331DOI Listing
July 2019

Tumor Microenvironment in T-Cell Lymphomas.

Cancer Treat Res 2019;176:69-82

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99716-2_3
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99716-2_3DOI Listing
July 2019

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

Leuk Res 2019 Jun 4;81:1-9. Epub 2019 Apr 4.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States; Department of Medical Oncology, Mayo Clinic 200 First St. SW, Rochester, MN, 55905.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.03.009DOI Listing
June 2019

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Authors:
Stephen M Ansell

Leuk Lymphoma 2019 May 11;60(5):1114-1115. Epub 2019 Jan 11.

a Division of Hematology , Mayo Clinic , Rochester , Minnesota 55905 , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1543887DOI Listing
May 2019

Immunotherapy in Hodgkin Lymphoma: The Road Ahead.

Authors:
Stephen M Ansell

Trends Immunol 2019 May 2;40(5):380-386. Epub 2019 Apr 2.

Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2019.03.003DOI Listing
May 2019

Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas.

Leuk Lymphoma 2019 May 1:1-3. Epub 2019 May 1.

a Division of Hematology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1608534DOI Listing
May 2019

The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma.

Authors:
Stephen M Ansell

Cancer Immunol Res 2019 May;7(5):696-700

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0890DOI Listing
May 2019

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides.

Invest New Drugs 2019 02 26;37(1):9-16. Epub 2018 Apr 26.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0606-9DOI Listing
February 2019

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

J Clin Oncol 2019 Jan 27;37(2):144-152. Epub 2018 Nov 27.

1 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Université de Lyon, Université Claude Bernard Lyon 1, Centre de Recherche en Cancérologie de Lyon INSERM 1052, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366812PMC
January 2019

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.

Authors:
Stephen M Ansell

Lancet Haematol 2019 Jan;6(1):e2-e3

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30210-2DOI Listing
January 2019

The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.

Hematol Oncol Clin North Am 2018 10 25;32(5):777-786. Epub 2018 Jul 25.

Division of Hematology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.05.005DOI Listing
October 2018

Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.

Nat Commun 2018 10 10;9(1):4182. Epub 2018 Oct 10.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, 20892, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-06541-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180091PMC
October 2018

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J Clin Oncol 2018 06 19;36(16):1603-1610. Epub 2018 Apr 19.

Matthew J. Maurer, Thomas M. Habermann, Carrie A. Thompson, Cristine Allmer, Patrick B. Johnston, Ivana N. Micallef, David J. Inwards, William R. Macon, Andrew L. Feldman, Susan L. Slager, Stephen M. Ansell, James R. Cerhan, Thomas E. Witzig, and Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN; Hervé Ghesquières and Gilles A. Salles, Université Claude Bernard, Lyon; Jean-Philippe Jais, Richard Delarue, Thierry J. Molina, Hopital Necker, Paris; Corinne Haioun, Groupe Hospitalier Mondor, Créteil; Frederic Peyrade, Centre Antoine Lacassagne, Nice; Olivier Fitoussi, Polyclinique Bordeaux Nord-Aquitaine, Bordeaux; Hervé Tilly, Centre de lutte Contre le Cancer Henri Becquerel, Rouen, France; Brian K. Link, Umar Farooq, Sergei Syrbu, and George J. Weiner, University of Iowa, Iowa City, IA; and Nicolas Ketterer, Clinique Bois-Cerf, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978469PMC
June 2018

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.

JAMA Oncol 2018 May;4(5):745-746

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.5100DOI Listing
May 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 05 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855PMC
May 2018

Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.

Authors:
Stephen M Ansell

Am J Hematol 2018 05;93(5):704-715

Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25071DOI Listing
May 2018

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.

J Hematol Oncol 2018 Apr 23;11(1):57. Epub 2018 Apr 23.

Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-018-0601-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914042PMC
April 2018

Reply to Castillo et al.

Am J Hematol 2018 03 5;93(3):E71-E73. Epub 2018 Feb 5.

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25029DOI Listing
March 2018

Primary central nervous system vasculitis associated with lymphoma.

Neurology 2018 03 2;90(10):e847-e855. Epub 2018 Feb 2.

From the Departments of Neurology (R.D.B.), Biomedical Statistics and Informatics (T.J.H.C.), Radiology (J.H.), Hematology (S.M.A.), Anatomic Pathology (C.G.), and Rheumatology (G.G.H.), Mayo Clinic, Rochester, MN; and Rheumatology Division (C.S.), Azienda USL-IRCCS di Reggio Emilia e Università di Modena e Reggio Emilia, Italy. Dr. Salvarani is currently a visiting clinician at the Department of Neurology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005062DOI Listing
March 2018

Acalabrutinib in mantle cell lymphoma.

Lancet 2018 02 11;391(10121):633-634. Epub 2017 Dec 11.

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)33256-7DOI Listing
February 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

N Engl J Med 2018 01 10;378(4):331-344. Epub 2017 Dec 10.

From the University of British Columbia and the Department of Medical Oncology, British Columbia Cancer Agency Centre for Lymphoid Cancer, Vancouver, Canada (J.M.C., K.J.S.); the Department of Hematology, Jagiellonian University, Krakow (W.J.), the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw (E.L.-M.), the Department of Hematology and Transfusion Medicine, Center of Postgraduate Medical Education, Warsaw (E.L.-M.), the Department of Experimental Hematology, Medical University of Lodz, Lodz (P.S.), and the Department of Lymphoid Malignancy, the Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw (J.W.) - all in Poland; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (D.J.S., A.Y.); the Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN (S.M.A.); the Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea (W.S.K.); Research Innovation and Statistics, Antoine-Lacassagne Cancer Center, Nice, France (A.G.); Petrov Research Institute of Oncology, St. Petersburg, Russia (S.A.); the Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen (Á.I.), and the Department of Hematology, National Institute of Oncology, Budapest (A.R.) - both in Hungary; the Department of Advanced Biomedical Science, Federico II University Hospital, Naples (M.P.), and the Institute of Hematology Seràgnoli, University of Bologna, Bologna (P.L.Z.) - both in Italy; the Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston (Y.O.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (T.F.); the Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis (N.L.B.); the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA (R.C.); the Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Center, Detroit (R.R.); Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton (D.C.), and the Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester (J.R.) - both in the United Kingdom; the Department of Clinical Development, Seattle Genetics, Bothell, WA (N.C.J., E.S.); and Oncology Clinical Research (J.S., H.A.J., D.H.) and Global Biostatistics (R.L.), Millennium Pharmaceuticals, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1708984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819601PMC
January 2018

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

J Clin Oncol 2017 Dec 26;35(36):4019-4026. Epub 2017 Oct 26.

Matthew J. Maurer, N. Nora Bennani, Stephen M. Ansell, James R. Cerhan, and Andrew L. Feldman, Mayo Clinic, Rochester, MN; Fredrik Ellin, Kalmar County Hospital, Kalmar; Fredrik Ellin and Thomas Relander, Lund University; Mats Jerkeman and Thomas Relander, Skåne University Hospital, Lund; Karin E. Smedby, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Line Srour, Joseph M. Connors, Graham W. Slack, and Kerry J. Savage, Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada; and Brian K. Link, University of Iowa Hospitals and Clinics, Iowa City, IA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.8195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736237PMC
December 2017

Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.

F1000Res 2017 18;6:2142. Epub 2017 Dec 18.

Department of Medicine, Division of Hematology, Mayo Clinic , Rochester, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.12880.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785715PMC
December 2017

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.

Authors:
Sasha Bernatsky Héctor A Velásquez García John J Spinelli Patrick Gaffney Karin E Smedby Rosalind Ramsey-Goldman Sophia S Wang Hans-Olov Adami Demetrius Albanes Emanuele Angelucci Stephen M Ansell Yan W Asmann Nikolaus Becker Yolanda Benavente Sonja I Berndt Kimberly A Bertrand Brenda M Birmann Heiner Boeing Paolo Boffetta Paige M Bracci Paul Brennan Angela R Brooks-Wilson James R Cerhan Stephen J Chanock Jacqueline Clavel Lucia Conde Karen H Cotenbader David G Cox Wendy Cozen Simon Crouch Anneclaire J De Roos Silvia de Sanjose Simonetta Di Lollo W Ryan Diver Ahmet Dogan Lenka Foretova Hervé Ghesquières Graham G Giles Bengt Glimelius Thomas M Habermann Corinne Haioun Patricia Hartge Henrik Hjalgrim Theodore R Holford Elizabeth A Holly Rebecca D Jackson Rudolph Kaaks Eleanor Kane Rachel S Kelly Robert J Klein Peter Kraft Anne Kricker Qing Lan Charles Lawrence Mark Liebow Tracy Lightfoot Brian K Link Marc Maynadie James McKay Mads Melbye Thierry J Molina Alain Monnereau Lindsay M Morton Alexandra Nieters Kari E North Anne J Novak Kenneth Offit Mark P Purdue Marco Rais Jacques Riby Eve Roman Nathaniel Rothman Gilles Salles Gianluca Severi Richard K Severson Christine F Skibola Susan L Slager Alex Smith Martyn T Smith Melissa C Southey Anthony Staines Lauren R Teras Carrie A Thompson Hervé Tilly Lesley F Tinker Anne Tjonneland Jenny Turner Claire M Vajdic Roel C H Vermeulen Joseph Vijai Paolo Vineis Jarmo Virtamo Zhaoming Wang Stephanie Weinstein Thomas E Witzig Andrew Zelenetz Anne Zeleniuch-Jacquotte Yawei Zhang Tongzhang Zheng Mariagrazia Zucca Ann E Clarke

Lupus Sci Med 2017 12;4(1):e000187. Epub 2017 Nov 12.

Division of Rheumatology, University of Calgary, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2016-000187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715504PMC
November 2017

Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly.

Leuk Lymphoma 2017 10 2;58(10):2273-2274. Epub 2017 Jun 2.

a Division of Hematology, Department of Medicine , Mayo Clinic , Rochester , MN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1326035DOI Listing
October 2017

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

JCO Precis Oncol 2017 1;2017. Epub 2017 Aug 1.

David L. Marks, Tara L. Hogenson, Anne M. Vrabel, Ashley N. Sigafoos, Ezequiel J. Tolosa, Ryan M. Carr, Stephanie L. Safgren, Elisa Enriquez Hesles, Luciana L. Almada, Paola A. Romecin-Duran, Eriko Iguchi, Aryan Ala'Aldeen, Jean-Pierre A. Kocher, Gavin R. Oliver, Naresh Prodduturi, David W. Mead, Asif Hossain, Norine E. Huneke, Colleen M. Tagtow, Sikander Ailawadhi, Stephen M. Ansell, Michaela S. Banck, Asher A. Chanan-Khan, Ronald S. Go, Thorvardur R. Halfdanarson, Richard W. Joseph, Prashant Kapoor, Aaron S. Mansfield, Amulya A. Nageswara Rao, Grzegorz S. Nowakowski, Animesh Pardanani, Sameer A. Parikh, John C. Cheville, Andrew L. Feldman, Ramesh K. Ramanathan, Steven I. Robinson, Heidi D. Finnes, Jennifer B. McCormick, Robert R. McWilliams, Aminah Jatoi, Mrinal M. Patnaik, Eric D. Wieben, Tammy M. McAllister, Kandelaria M. Rumilla, Sarah E. Kerr, Konstantinos N. Lazaridis, Gianrico Farrugia, Karl J. Clark, Eric W. Klee, and Martin E. Fernandez-Zapico, Mayo Clinic, Rochester; Ernesto Resnik, Bio-Techne, Minneapolis, MN; Sikander Ailawadhi, Asher A. Chanan-Khan, and Richard W. Joseph, Mayo Clinic, Jacksonville, FL; Jan B. Egan, Alan H. Bryce, Estrella M. Carballido, KellyK. Curtis, Chelsea D. Gawryletz, Thai H. Ho,Nathalie Meurice, Ramesh K. Ramanathan, Raoul Tibes, Alvin C. Silva, A. Keith Stewart, and Mitesh J. Borad, Mayo Clinic, Phoenix, AZ; and Eileen J. Kennedy, University of Georgia, Athens, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369924PMC
August 2017

Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.

Cancer Treat Res 2016;169:321-361

Mayo Clinic, Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_16DOI Listing
June 2017

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Blood 2017 06 21;129(22):3037-3039. Epub 2017 Mar 21.

Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-757740DOI Listing
June 2017

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

J Clin Oncol 2017 Jun 2;35(18):2028-2036. Epub 2017 May 2.

Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.1508
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.1508DOI Listing
June 2017

Immunotherapy in lymphoma.

Hematol Oncol 2017 Jun;35 Suppl 1:88-91

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2408DOI Listing
June 2017

Nivolumab in the Treatment of Hodgkin Lymphoma.

Authors:
Stephen M Ansell

Clin Cancer Res 2017 Apr 23;23(7):1623-1626. Epub 2016 Nov 23.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1387DOI Listing
April 2017

Anti-CD20-IL-21 fusokine: the tail wags the dog.

Authors:
Stephen M Ansell

Blood 2017 04;129(16):2209-2210

MAYO CLINIC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-02-767541DOI Listing
April 2017

Recommendations for Clinical Trial Development in Follicular Lymphoma.

J Natl Cancer Inst 2017 03 31;109(3). Epub 2016 Dec 31.

Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059137PMC
March 2017

Waldenström macroglobulinemia: biology, genetics, and therapy.

Blood Lymphat Cancer 2016 26;6:49-58. Epub 2016 Jul 26.

Division of Hematology,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BLCTT.S84157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467336PMC
July 2016

Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

Semin Hematol 2016 Jul 13;53(3):186-9. Epub 2016 May 13.

Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2016.05.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572135PMC
July 2016

Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.

Best Pract Res Clin Haematol 2016 06 4;29(2):148-155. Epub 2016 Sep 4.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.016DOI Listing
June 2016

Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.

Best Pract Res Clin Haematol 2016 06 23;29(2):179-186. Epub 2016 Aug 23.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117990PMC
June 2016